Skip to content

Oral Fenretinide

Difficult-to-treat cancers may benefit from administration of cytotoxic retinoid N-(4-hydroxyphenyl) retinamide (4-HPR; fenretinide)

Published: 19th November 2019
Oral Fenretinide
Header image is purely illustrative. Ed Uthman, Non-small Cell Carcinoma of the Lung, FNA, flickr.com / CC BY 2.0
IP Status
  • Patented
Seeking
  • Licensing
  • Development partner